We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-2.31%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.53B
AUM Growth
-$239M
Cap. Flow
-$4.03M
Cap. Flow %
-0.26%
Top 10 Hldgs %
79.89%
Holding
32
New
1
Increased
4
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
NAUT icon
Nautilus Biotechnolgy
NAUT
+$10.8M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.7M
3
DVAX
Dynavax Technologies
DVAX
+$7.96M
4
PANA
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
+$5.01M
5
TNGX icon
Tango Therapeutics
TNGX
+$4.74M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$32.7M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 88.31%
2 Financials 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PANA
26
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$5.01M 0.33%
+500,000
New +$5.01M
OMEG
27
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$3.98M 0.26%
400,000
– –
FLACU
28
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$3.02M 0.2%
300,000
– –
JYAC
29
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.98M 0.2%
300,000
– –
MLTX icon
30
MoonLake Immunotherapeutics
MLTX
$1.47B
$2.59M 0.17%
250,000
– –
PNT
31
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-1,000,000
Closed -$10.5M
CNST
32
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-1,400,000
Closed -$32.7M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q2 2021 Portfolio in Review

As of Q2 2021, Bain Capital Life Sciences Investors held 32 positions worth $1.53B, down 14% from $1.77B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Bain Capital Life Sciences Investors's Q2 2021 filing shows 1 new, 4 increased and 2 closed positions. Its largest new stake was Panacea Acquisition Corp. II Class A Ordinary Shares: 500,000 shares worth $5.01M. The largest sale was Constellation Pharmaceuticals, Inc., an estimated $32.7M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Financials.

  • Bain Capital Life Sciences Investors's largest Q2 2021 buy was Panacea Acquisition Corp. II Class A Ordinary Shares: 500,000 shares worth $5.01M.
  • Bain Capital Life Sciences Investors added most to Nautilus Biotechnolgy in Q2 2021, an estimated $10.8M increase.
  • Bain Capital Life Sciences Investors fully exited Constellation Pharmaceuticals, Inc. in Q2 2021, selling an estimated $32.7M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 80% of its $1.53B portfolio in Q2 2021.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 2 in Q2 2021.
  • Bain Capital Life Sciences Investors's portfolio value fell 14% quarter-over-quarter to $1.53B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2021, filed 16 Aug 2021.